keyword
MENU ▼
Read by QxMD icon Read
search

Ibs and probiotics

keyword
https://www.readbyqxmd.com/read/29881616/effect-of-lactobacillus-paracasei-cncm-i-1572-on-symptoms-gut-microbiota-short-chain-fatty-acids-and-immune-activation-in-patients-with-irritable-bowel-syndrome-a-pilot-randomized-clinical-trial
#1
Cesare Cremon, Simone Guglielmetti, Giorgio Gargari, Valentina Taverniti, Anna Maria Castellazzi, Chiara Valsecchi, Carlotta Tagliacarne, Walter Fiore, Massimo Bellini, Lorenzo Bertani, Dario Gambaccini, Michele Cicala, Bastianello Germanà, Maurizio Vecchi, Isabella Pagano, Maria Raffaella Barbaro, Lara Bellacosa, Vincenzo Stanghellini, Giovanni Barbara
Background: Evidence suggests a role of intestinal microbiota-host interactions in the pathophysiology and symptoms of irritable bowel syndrome (IBS). Objective: The objective of this article is to assess the effects of Lactobacillus paracasei CNCM I-1572 on clinical and gut microbiota-related factors in IBS. Methods: We conducted a multicenter, randomized, double-blind, cross-over, 18-week, placebo-controlled, pilot trial assessing the effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota composition, fecal short chain fatty acid (SCFA), immunoglobulin A, and cytokines in IBS...
May 2018: United European Gastroenterology Journal
https://www.readbyqxmd.com/read/29876777/probiotics-ameliorate-stool-consistency-in-patients-with-chronic-constipation-a-randomized-double-blind-placebo-controlled-study
#2
Jin Young Yoon, Jae Myung Cha, Ju Kyoung Oh, Pei Lei Tan, Sae Hun Kim, Min Seob Kwak, Jung Won Jeon, Hyun Phil Shin
BACKGROUND/AIMS: The efficacy of probiotics for improving clinical symptoms, altering the fecal microbiota, and regulating serum immune cytokine levels was investigated in patients with irritable bowel syndrome-constipation (IBS-C) or functional constipation (FC). METHODS: A randomized, double-blind, placebo-controlled trial was conducted at Kyung Hee University Hospital between October 2016 and February 2017. Consecutive 18-75-year-old patients with diagnosis of IBS-C or FC (based on Rome IV criteria) consumed probiotics (3...
June 7, 2018: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/29801486/a-randomized-placebo-controlled-clinical-trial-of-a-multi-strain-probiotic-formulation-bio-kult%C3%A2-in-the-management-of-diarrhea-predominant-irritable-bowel-syndrome
#3
Shamsuddin M Ishaque, S M Khosruzzaman, Dewan Saifuddin Ahmed, Mukesh Prasad Sah
BACKGROUND: Accumulating evidence supports the view that an imbalance of gut bacteria contributes to IBS, and that increasing the mass of beneficial species may reduce the numbers of pathogenic bacteria and help alleviate symptoms. METHODS: In this double-blind trial 400 adult patients with moderate-to-severe symptomatic diarrhea-predominant IBS (IBS-D) were randomized to treatment with the multi-strain probiotic Bio-Kult® (14 different bacterial strains) or placebo for 16 weeks...
May 25, 2018: BMC Gastroenterology
https://www.readbyqxmd.com/read/29785336/targeting-the-microbiota-from-irritable-bowel-syndrome-to-mood-disorders-focus-on-probiotics-and-prebiotics
#4
M M Pusceddu, K Murray, M G Gareau
Purpose of review: The crosstalk between the gut and the brain has revealed a complex communication system responsible for maintaining a proper gastrointestinal homeostasis as well as affect emotional mood and cognitive functions. Recent research has revealed that beneficial manipulation of the microbiota by probiotics and prebiotics represent an emerging and novel strategy for the treatment of a large spectrum of diseases ranging from visceral pain to mood disorders. The review critically evaluates current knowledge of the effects exerted by both probiotics and prebiotics in irritable bowel syndrome (IBS) and mood disorders such as anxiety and depression...
March 2018: Current Pathobiology Reports
https://www.readbyqxmd.com/read/29748817/the-role-of-the-microbiome-for-human-health-from-basic-science-to-clinical-applications
#5
M Hasan Mohajeri, Robert J M Brummer, Robert A Rastall, Rinse K Weersma, Hermie J M Harmsen, Marijke Faas, Manfred Eggersdorfer
The 2017 annual symposium organized by the University Medical Center Groningen in The Netherlands focused on the role of the gut microbiome in human health and disease. Experts from academia and industry examined interactions of prebiotics, probiotics, or vitamins with the gut microbiome in health and disease, the development of the microbiome in early-life and the role of the microbiome on the gut-brain axis. The gut microbiota changes dramatically during pregnancy and intrinsic factors (such as stress), in addition to extrinsic factors (such as diet, and drugs) influence the composition and activity of the gut microbiome throughout life...
May 10, 2018: European Journal of Nutrition
https://www.readbyqxmd.com/read/29695183/efficacy-of-bacillus-coagulans-unique-is2-in-treatment-of-irritable-bowel-syndrome-in-children-a-double-blind-randomised-placebo-controlled-study
#6
M Ratna Sudha, N Jayanthi, M Aasin, R D Dhanashri, T Anirudh
The efficacy of the probiotic strain, Bacillus coagulans Unique IS2 in the treatment of Irritable Bowel Syndrome (IBS) was evaluated in children. A total of 141 children of either sex in the age group 4-12 years, diagnosed with IBS according to the Rome III criteria, participated in the double-blind randomised controlled trial. Children received either B. coagulans Unique IS2 chewable tablets or placebo once daily for eight weeks followed by a two week follow-up period. Reduction in pain intensity as well as other symptoms associated with Irritable Bowel Syndrome like abdominal discomfort, bloating, distension, sense of incomplete evacuation, straining at stool, urgency of bowel movement, passage of gas and mucus, and bowel habit satisfaction were assessed...
June 15, 2018: Beneficial Microbes
https://www.readbyqxmd.com/read/29694952/dysbiosis-in-functional-bowel-disorders
#7
Paul Enck, Nazar Mazurak
Functional bowel disorders (FBD) resemble a group of diseases of the gastrointestinal (GI) tract that are without a clear pathogenesis; the best known is probably the "irritable bowel syndrome" (IBS). Only recently we have been able to explore the role of the gut microbiota in FBD due to progress in microbiological analytic techniques. There are different ways to explore the role of the gut microbiota and its dysbiosis in FBD. Comparison of the microbial composition in a group of patients with FBD, for example, with IBS to a group of healthy volunteers is one way...
2018: Annals of Nutrition & Metabolism
https://www.readbyqxmd.com/read/29688915/clinical-and-microbiological-effect-of-a-multispecies-probiotic-supplementation-in-celiac-patients-with-persistent-ibs-type-symptoms-a-randomized-double-blind-placebo-controlled-multicenter-trial
#8
Ruggiero Francavilla, Maria Piccolo, Antonio Francavilla, Lorenzo Polimeno, Francesco Semeraro, Fernanda Cristofori, Stefania Castellaneta, Michele Barone, Flavia Indrio, Marco Gobbetti, Maria De Angelis
GOALS: The goals of this study were to evaluate the efficacy and safety of a probiotic mixture in patients with celiac disease (CD) with irritable bowel syndrome (IBS)-type symptoms despite a strict gluten-free diet (GFD). BACKGROUND: About 30% of patients with CD adherent to a GFD suffer from IBS-type symptoms; a possible cause resides in the imbalances of the intestinal microbiota in CD. Probiotics may represent a potential treatment. STUDY: CD patients with IBS-type symptoms entered a prospective, double-blind, randomized placebo-controlled study...
April 23, 2018: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/29610559/a-double-blind-placebo-controlled-randomized-clinical-trial-that-breast-milk-derived-lactobacillus-gasseri-bnr17-mitigated-diarrhea-dominant-irritable-bowel-syndrome
#9
Suk Pyo Shin, Yoon Mi Choi, Won Hee Kim, Sung Pyo Hong, Jong-Min Park, Joohee Kim, Oran Kwon, Eun Hyun Lee, Ki Baik Hahm
The exact pathogenesis of diarrhea-dominant irritable bowel syndrome (IBS) is not known, but the abnormal microbiota of the gastrointestinal tract is considered to be one of the important contributing factors as in other gastrointestinal diseases such as inflammatory bowel disease, antibiotic-associated diarrhea, and colorectal cancer as well as systemic diseases. Though diverse trials of probiotics had been continued in the treatment of diarrhea-IBS, only a few proved by randomized clinical trial. To prove the efficacy of Lactobacillus gasseri BNR17 isolated from breast milk in patients with diarrhea-IBS, prospective, randomized, placebo controlled clinical trial was done including health related-quality of life analysis, colon transit time, and the changes of fecal microbiota...
March 2018: Journal of Clinical Biochemistry and Nutrition
https://www.readbyqxmd.com/read/29605976/clinical-practice-guidelines-for-irritable-bowel-syndrome-in-korea-2017-revised-edition
#10
REVIEW
Kyung Ho Song, Hye-Kyung Jung, Hyun Jin Kim, Hoon Sup Koo, Yong Hwan Kwon, Hyun Duk Shin, Hyun Chul Lim, Jeong Eun Shin, Sung Eun Kim, Dae Hyeon Cho, Jeong Hwan Kim, Hyun Jung Kim
In 2011, the Korean Society of Neurogastroenterology and Motility (KSNM) published clinical practice guidelines on the management of irritable bowel syndrome (IBS) based on a systematic review of the literature. The KSNM planned to update the clinical practice guidelines to support primary physicians, reduce the socioeconomic burden of IBS, and reflect advances in the pathophysiology and management of IBS. The present revised version of the guidelines is in continuity with the previous version and targets adults diagnosed with, or suspected to have, IBS...
April 30, 2018: Journal of Neurogastroenterology and Motility
https://www.readbyqxmd.com/read/29529042/protease-signaling-through-protease-activated-receptor-1-mediate-nerve-activation-by-mucosal-supernatants-from-irritable-bowel-syndrome-but-not-from-ulcerative-colitis-patients
#11
Sabine Buhner, Hannes Hahne, Kerstin Hartwig, Qin Li, Sheila Vignali, Daniela Ostertag, Chen Meng, Gabriele Hörmannsperger, Breg Braak, Christian Pehl, Thomas Frieling, Giovanni Barbara, Roberto De Giorgio, Ihsan Ekin Demir, Güralp Onur Ceyhan, Florian Zeller, Guy Boeckxstaens, Dirk Haller, Bernhard Kuster, Michael Schemann
BACKGROUND & AIMS: The causes of gastrointestinal complaints in irritable bowel syndrome (IBS) remain poorly understood. Altered nerve function has emerged as an important pathogenic factor as IBS mucosal biopsy supernatants consistently activate enteric and sensory neurons. We investigated the neurally active molecular components of such supernatants from patients with IBS and quiescent ulcerative colitis (UC). METHOD: Effects of supernatants from 7 healthy controls (HC), 20 IBS and 12 UC patients on human and guinea pig submucous neurons were studied with neuroimaging techniques...
2018: PloS One
https://www.readbyqxmd.com/read/29528206/functional-gastrointestinal-disorders-functional-lower-gastrointestinal-disorders-in-adults
#12
Michael Malone, Abdul Waheed, Samiullah Samiullah
Functional lower gastrointestinal disorders include irritable bowel syndrome (IBS), functional constipation, functional fecal incontinence, and functional anorectal pain. These disorders are common and have significant medical and social effects. They also can be challenging to manage. Patients with mild symptoms may benefit from lifestyle modification. IBS is classified into two subtypes: diarrhea-predominant and constipation-predominant. Depending on the IBS subtype and its likely etiology, patients may benefit from treatment with antispasmodics, antidepressants, guanylate cyclase-C agonists, chloride channel activators, antidiarrheal agents, probiotics, and/or antibiotics...
March 2018: FP Essentials
https://www.readbyqxmd.com/read/29508268/effect-of-a-preparation-of-four-probiotics-on-symptoms-of-patients-with-irritable-bowel-syndrome-association-with-intestinal-bacterial-overgrowth
#13
Konstantinos Leventogiannis, Paraskevas Gkolfakis, Georgios Spithakis, Aikaterini Tsatali, Aikaterini Pistiki, Athanasios Sioulas, Evangelos J Giamarellos-Bourboulis, Konstantinos Triantafyllou
The effect of probiotics on small intestinal bacterial overgrowth (SIBO) in irritable bowel syndrome (IBS) has never been studied so far. In this prospective trial, five patients with IBS and SIBO and 21 patients with IBS without SIBO were administered an oral capsule containing Saccharomyces boulardii, Bifidobacterium lactis, Lactobacillus acidophilus, and Lactobacillus plantarum (Lactolevure® ) every 12 h for 30 days. SIBO was defined by quantitative culture of the third part of the duodenum; IBS was defined by the Rome III criteria...
March 5, 2018: Probiotics and Antimicrobial Proteins
https://www.readbyqxmd.com/read/29498019/a-review-of-microbiota-and-irritable-bowel-syndrome-future-in-therapies
#14
REVIEW
Bruno K Rodiño-Janeiro, María Vicario, Carmen Alonso-Cotoner, Roberto Pascua-García, Javier Santos
Irritable bowel syndrome (IBS), one of the most frequent digestive disorders, is characterized by chronic and recurrent abdominal pain and altered bowel habit. The origin seems to be multifactorial and is still not well defined for the different subtypes. Genetic, epigenetic and sex-related modifications of the functioning of the nervous and immune-endocrine supersystems and regulation of brain-gut physiology and bile acid production and absorption are certainly involved. Acquired predisposition may act in conjunction with infectious, toxic, dietary and life event-related factors to enhance epithelial permeability and elicit mucosal microinflammation, immune activation and dysbiosis...
March 2018: Advances in Therapy
https://www.readbyqxmd.com/read/29493330/fecal-microbiota-transplantation-for-managing-irritable-bowel-syndrome
#15
Magdy El-Salhy, Tarek Mazzawi
Irritable bowel syndrome (IBS) is a widespread gastrointestinal disorder affecting 11.2% of the world adult population. The intestinal microbiome is thought to play a pivotal role in the pathophysiology of IBS. The composition of the fecal microbiome in IBS patients differs from that in healthy individuals, but the exact bacteria species involved in the development of IBS remain to be determined. There is also an imbalance between useful and harmful bacteria (dysbiosis) in the intestinal microbiome in patients with IBS...
May 2018: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29464501/a-systematic-review-of-probiotic-interventions-for-gastrointestinal-symptoms-and-irritable-bowel-syndrome-in-chronic-fatigue-syndrome-myalgic-encephalomyelitis-cfs-me
#16
REVIEW
Matthew Corbitt, N Campagnolo, D Staines, S Marshall-Gradisnik
Gastrointestinal (GI) symptoms and irritable bowel (IB) symptoms have been associated with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). The aim of this study was to conduct a systematic review of these symptoms in CFS/ME, along with any evidence for probiotics as treatment. Pubmed, Scopus, Medline (EBSCOHost) and EMBASE databases were searched to source relevant studies for CFS/ME. The review included any studies examining GI symptoms, irritable bowel syndrome (IBS) and/or probiotic use. Studies were required to report criteria for CFS/ME and study design, intervention and outcome measures...
February 20, 2018: Probiotics and Antimicrobial Proteins
https://www.readbyqxmd.com/read/29460487/systematic-review-probiotics-in-the-management-of-lower-gastrointestinal-symptoms-an-updated-evidence-based-international-consensus
#17
REVIEW
A P S Hungin, C R Mitchell, P Whorwell, C Mulligan, O Cole, L Agréus, P Fracasso, C Lionis, J Mendive, J-M Philippart de Foy, B Seifert, K-A Wensaas, C Winchester, N de Wit
BACKGROUND: In 2013, a systematic review and Delphi consensus reported that specific probiotics can benefit adult patients with irritable bowel syndrome (IBS) and other gastrointestinal (GI) problems. AIM: To update the consensus with new evidence. METHODS: A systematic review identified randomised, placebo-controlled trials published between January 2012 and June 2017. Evidence was graded, previously developed statements were reassessed by an 8-expert panel, and agreement was reached via Delphi consensus...
April 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29451186/-lactobacillus-acidophilus-and-bifidobacterium-longum-supernatants-upregulate-the-serotonin-transporter-expression-in-intestinal-epithelial-cells
#18
Ya-Nan Cao, Li-Juan Feng, Bang-Mao Wang, Kui Jiang, Shu Li, Xin Xu, Wei-Qiang Wang, Jing-Wen Zhao, Yu-Ming Wang
Background/Aims: Probiotics play a role in relieving irritable bowel syndrome (IBS); however, the underlying mechanism is yet unclear. The aim of the study was to investigate the effects of the supernatants of Lactobacillus acidophilus and Bifidobacterium longum on the expression of serotonin transporter (SERT) messenger ribonucleic acid (mRNA) and protein. Materials and Methods: HT-29 and Caco-2 cells were treated with different concentrations of L. acidophilus and B...
January 2018: Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association
https://www.readbyqxmd.com/read/29446765/gut-microbiota-based-therapies-for-irritable-bowel-syndrome
#19
Emily K Stern, Darren M Brenner
Irritable bowel syndrome (IBS) is a common, heterogeneous disorder characterized by abdominal pain associated with changes in bowel habits. The pathogenesis of IBS is multifactorial and may relate to alterations in the gut microbiota, changes in visceral sensation and motility, and genetic and environmental factors. Administration of systemic antibiotics may increase the risk of IBS by altering gastrointestinal homeostasis. Therapeutic interventions for IBS with diarrhea that are thought to target alterations in the gut microbiota include the nonsystemic antibiotic rifaximin, the medical food serum-derived bovine immunoglobulin, prebiotics, probiotics, and dietary modification...
February 15, 2018: Clinical and Translational Gastroenterology
https://www.readbyqxmd.com/read/29445178/the-effect-of-clostridium-butyricum-on-symptoms-and-fecal-microbiota-in-diarrhea-dominant-irritable-bowel-syndrome-a-randomized-double-blind-placebo-controlled-trial
#20
Yi-Yuan Sun, Ming Li, Yue-Yue Li, Li-Xiang Li, Wen-Zhe Zhai, Peng Wang, Xiao-Xiao Yang, Xiang Gu, Li-Jin Song, Zhen Li, Xiu-Li Zuo, Yan-Qing Li
Irritable bowel syndrome (IBS) is a common disorder in gastrointestinal system and impairs the quality of life of the patients. Clostridium butyricum (CB) is a probiotics that has been used in several gastrointestinal diseases. The efficacy of CB in treating IBS is still unknown. This prospective, multi-centre, randomized, double-blind, placebo-controlled trial aimed to assess the efficacy and safety of CB in treating diarrhea-predominant IBS (IBS-D) and analyze the fecal microbiota after treatment. Two hundred patients with IBS-D were recruited and were given CB or placebo for 4 weeks...
February 14, 2018: Scientific Reports
keyword
keyword
32581
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"